{"prompt": "['patients with HCC than with RCC. Across clinical studies enrolling 1327 LENVIMA-treated', 'patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4%', 'of patients. Fatal events, including hepatic failure, acute hepatitis and hepatorenal syndrome,', 'occurred in 0.5% of patients. Patients with worse hepatic impairment and/or greater liver tumor', 'burden at baseline had a higher risk of developing hepatic encephalopathy and hepatic failure.', 'Hepatic encephalopathy also occurred more frequently in patients aged 75 years and older.', 'Approximately half of the events of hepatic failure were reported in patients with disease', 'progression.', 'Regular monitoring of liver function should be monitored as per the Trial Flow Chart (Section', '6.0). As per standard of care, we plan to monitor liver enzymes (including AST and ALT) every', '2 weeks for the first 2 months of lenvatinib administration.', 'Any change in liver function should be graded according to CTCAE v4.0 (Appendix 2). In the', 'case of a decrease in liver function by 1 grade or more from baseline, Table 3 (Dose', 'Modifications for Lenvatinib Treatment-Related Toxicity) should be followed. If hepatic failure', 'occurs, the study drug must be discontinued.', '5.2.2.2.5 Management of Thromboembolic Events', 'Both venous and arterial thromboembolism have been reported at an increased frequency in', 'patients receiving lenvatinib. Study participants should be advised to self-assess for any', 'symptoms consistent with venous thromboembolism (VTE) including symptoms of acute onset', 'of dyspnea, chest pain, tachycardia, tachypnea, fever, hemoptysis, and cough and symptoms of', 'lower extremity deep venous thrombosis (DVT) such as unilateral swelling, tenderness,', 'erythema or warmth. If a thromboembolic event is diagnosed, appropriate supportive care should', 'be provided together with close monitoring. The instructions for managing study drug described', 'in Table 3 (Dose Modifications for Lenvatinib Treatment-Related Toxicity) should be followed.', 'If a subject experiences life-threatening (Grade 4) thromboembolic reactions, including', 'pulmonary embolism, the study drug must be discontinued.', '5.2.2.2.6 Management of Hemorrhagic Events', 'Serious hemorrhagic events have been reported in patients treated with lenvatinib. History,', 'physical exam and complete blood count (CBC) measurements should be serially assessed as per', 'the Trial Flow Chart (Section 6.0). Lenvatinib should be discontinued in subjects with serious', 'and life-threatening bleeding events or recent hemoptysis ( 2.5 mL of red blood).', '5.2.2.2.7 Management of Wound Healing Complications', 'No formal studies of the effect of lenvatinib on wound healing have been conducted but impaired', 'wound healing has been reported in patients receiving lenvatinib. To prevent difficulty with', 'wound healing, lenvatinib should be held for 2 days prior to a minor procedure (e.g. needle', 'biopsy) and restarted 2 days after given evidence of adequate healing and hemostasis. For major', 'procedures (e.g. requiring general anesthesia), lenvatinib should be stopped 1 week (5 half-lives)', 'Page 21', 'Version Date: 02/09/2020']['before the procedure and then restarted once there is clear wound healing and adequate', 'hemostasis (at least 1 week after the procedure). Any wounds should be monitored for wound', 'dehiscence, wound infection and other signs of impaired wound healing after lenvatinib is', 'resumed. If dehiscence occurs, lenvatinib should be interrupted until complete healing has taken', 'place.', '5.2.2.2.8 Management of Gastrointestinal (GI) Disorders', '5.2.2.2.8.1 Fistula Formation and GI Perforation', 'Events of fistula formation or gastrointestinal perforation and their sequelae have been reported', 'in patients treated with lenvatinib. Fistulas (e.g. gastrointestinal, bronchopleural, trachea-', 'esophageal, cutaneous, pharyngeal, female genital tract fistula) have been reported in lenvatinib', 'clinical trials and in post-marketing experience. In addition, pneumothorax has been reported', 'with and without clear evidence of a bronchopleural fistula. Some reports of gastrointestinal', 'perforation, fistula and pneumothorax occurred in association with tumor regression or necrosis.', 'In most cases of fistula formation or gastrointestinal perforation, risk factors such as prior', 'surgery or radiotherapy were present.', 'Discontinue treatment with lenvatinib and initiate appropriate management in subjects who have', 'been diagnosed with GI perforation or fistula.', '5.2.2.2.8.2 Diarrhea', 'Diarrhea is one of the most common AEs noted during lenvatinib treatment and should be', 'managed as per Table 6.', 'Table 5. Management of Diarrhea Associated with Lenvatinib', 'Page 22', 'Version Date: 02/09/2020']\n\n###\n\n", "completion": "END"}